Shares of Fresenius Medical Care AG (NYSE:FMS - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $30.46 and last traded at $29.78, with a volume of 648023 shares. The stock had previously closed at $29.85.
Analyst Ratings Changes
Several equities analysts have commented on the company. Morgan Stanley reissued an "underweight" rating on shares of Fresenius Medical Care in a research report on Thursday, May 15th. Truist Financial boosted their price target on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday, May 12th. Finally, Wall Street Zen began coverage on shares of Fresenius Medical Care in a research report on Tuesday, May 20th. They issued a "strong-buy" rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $27.80.
View Our Latest Stock Analysis on FMS
Fresenius Medical Care Stock Up 1.6%
The company has a market capitalization of $17.30 billion, a PE ratio of 24.37, a P/E/G ratio of 0.76 and a beta of 0.85. The business has a 50-day moving average of $25.61 and a 200 day moving average of $24.09. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.
Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. The business had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. Equities research analysts predict that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.
Fresenius Medical Care Increases Dividend
The company also recently announced an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 23rd will be given a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This is a positive change from Fresenius Medical Care's previous annual dividend of $0.44. This represents a yield of 1.9%. Fresenius Medical Care's payout ratio is 49.11%.
Hedge Funds Weigh In On Fresenius Medical Care
A number of large investors have recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of Fresenius Medical Care by 50.0% in the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company's stock worth $26,982,000 after purchasing an additional 361,364 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Fresenius Medical Care by 14.2% in the first quarter. AQR Capital Management LLC now owns 14,297 shares of the company's stock worth $356,000 after buying an additional 1,777 shares during the last quarter. Advisors Asset Management Inc. grew its stake in shares of Fresenius Medical Care by 243.3% during the 1st quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company's stock worth $195,000 after purchasing an additional 5,540 shares during the period. Vident Advisory LLC grew its position in Fresenius Medical Care by 131.8% during the first quarter. Vident Advisory LLC now owns 54,274 shares of the company's stock valued at $1,351,000 after buying an additional 30,864 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Fresenius Medical Care by 5.0% in the 1st quarter. Northern Trust Corp now owns 380,251 shares of the company's stock valued at $9,468,000 after purchasing an additional 18,061 shares in the last quarter. Institutional investors own 8.37% of the company's stock.
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
